NCT07476027

Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

Efficacy and Safety of CD7 CAR-T Cell in Newly Diagnosed High-Risk T-LBL/ALL

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an open, single-center, prospective clinical trial, with newly diagnosed high-risk T-LBL/ALL patients as the subjects. It plans to enroll 10 subjects. All patients will undergo lymphocyte collection during the CR1 remission period, followed by the preparation and reinfusion of CD7 CAR-T cells. Adverse reactions will be followed up and observed, and relevant data on treatment efficacy will be collected to evaluate the safety, efficacy, and cell metabolic kinetics characteristics of CAR-T cell therapy for the patients.

Conditions

• T Lymphoblastic Lymphoma
• T Acute Lymphoblastic Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	CD7 CAR-T cell intravenous infusion	CD7 CAR-T cells, single intravenous infusion

Timeline

• Start date: 2026-03-15
• Primary completion: 2029-04-01
• Completion: 2029-06-27
• First posted: 2026-03-17
• Last updated: 2026-03-17